Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer.
Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W.
Am J Pathol. 2012 Mar;180(3):895-903. Epub 2012 Jan 11.
Related citations
Clinical and biological significance of KISS1 expression in prostate cancer.
Wang H, Jones J, Turner T, He QP, Hardy S, Grizzle WE, Welch DR, Yates C.
Am J Pathol. 2012 Mar;180(3):1170-8. Epub 2012 Jan 6.
Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer.
Shirotake S, Miyajima A, Kosaka T, Tanaka N, Kikuchi E, Mikami S, Okada Y, Oya M.
Am J Pathol. 2012 Mar;180(3):1008-16. Epub 2012 Jan 6.
PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer.
Conley-LaComb MK, Huang W, Wang S, Shi D, Jung YS, Najy A, Fridman R, Bonfil RD, Cher ML, Chen YQ, Kim HR.
Am J Pathol. 2012 Mar;180(3):1017-27. Epub 2011 Dec 28.
FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.
Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T, Müntener M, Kristiansen G.
Am J Pathol. 2012 Feb;180(2):848-61. Epub 2011 Dec 2.
Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-β treatment.
Massoner P, Ladurner Rennau M, Heidegger I, Kloss-Brandstätter A, Summerer M, Reichhart E, Schäfer G, Klocker H.
Am J Pathol. 2011 Dec;179(6):2905-19. Epub 2011 Oct 6.
Integrin αv expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer.
van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC, van der Pluijm G.
Am J Pathol. 2011 Nov;179(5):2559-68. Epub 2011 Sep 9.
Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation.
Bekes EM, Schweighofer B, Kupriyanova TA, Zajac E, Ardi VC, Quigley JP, Deryugina EI.
Am J Pathol. 2011 Sep;179(3):1455-70. Epub 2011 Jul 8.
Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome.
Josefsson A, Adamo H, Hammarsten P, Granfors T, Stattin P, Egevad L, Laurent AE, Wikström P, Bergh A.
Am J Pathol. 2011 Oct;179(4):1961-8. Epub 2011 Aug 18.
Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer.
Svensson RU, Haverkamp JM, Thedens DR, Cohen MB, Ratliff TL, Henry MD.
Am J Pathol. 2011 Jul;179(1):502-12. Epub 2011 May 7.
Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases.
Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktaş M, Hwang MS, Darling DS, Coleman IM, Nelson PS, Nguyen HM, Corey E, Tewari M, Morrissey C, Vessella RL, Knudsen BS.
Am J Pathol. 2011 Jul;179(1):400-10. Epub 2011 May 4.
Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy.
Long Q, Johnson BA, Osunkoya AO, Lai YH, Zhou W, Abramovitz M, Xia M, Bouzyk MB, Nam RK, Sugar L, Stanimirovic A, Williams DJ, Leyland-Jones BR, Seth AK, Petros JA, Moreno CS.
Am J Pathol. 2011 Jul;179(1):46-54. Epub 2011 May 3.
RREB1 transcription factor splice variants in urologic cancer.
Nitz MD, Harding MA, Smith SC, Thomas S, Theodorescu D.
Am J Pathol. 2011 Jul;179(1):477-86.
Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition.
Martin P, Liu YN, Pierce R, Abou-Kheir W, Casey O, Seng V, Camacho D, Simpson RM, Kelly K.
Am J Pathol. 2011 Jul;179(1):422-35. Epub 2011 May 13.
Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.
Arbini AA, Greco M, Yao JL, Bourne P, Marra E, Hsieh JT, di Sant'agnese PA, Moro L.
Am J Pathol. 2011 May;178(5):2367-76.
The androgen-regulated Calcium-Activated Nucleotidase 1 (CANT1) is commonly overexpressed in prostate cancer and is tumor-biologically relevant in vitro.
Gerhardt J, Steinbrech C, Büchi O, Behnke S, Bohnert A, Fritzsche F, Liewen H, Stenner F, Wild P, Hermanns T, Müntener M, Dietel M, Jung K, Stephan C, Kristiansen G.
Am J Pathol. 2011 Apr;178(4):1847-60.
Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene.
Koh CM, Gurel B, Sutcliffe S, Aryee MJ, Schultz D, Iwata T, Uemura M, Zeller KI, Anele U, Zheng Q, Hicks JL, Nelson WG, Dang CV, Yegnasubramanian S, De Marzo AM.
Am J Pathol. 2011 Apr;178(4):1824-34.
This Month in AJP.
[No authors listed]
Am J Pathol. 2011 Apr;178(4):1415. No abstract available.
Suppression of prostate cancer cell rolling and adhesion to endothelium by 1α,25-dihydroxyvitamin D3.
Hsu JW, Yasmin-Karim S, King MR, Wojciechowski JC, Mickelsen D, Blair ML, Ting HJ, Ma WL, Lee YF.
Am J Pathol. 2011 Feb;178(2):872-80.
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.
Vainio P, Gupta S, Ketola K, Mirtti T, Mpindi JP, Kohonen P, Fey V, Perälä M, Smit F, Verhaegh G, Schalken J, Alanen KA, Kallioniemi O, Iljin K.
Am J Pathol. 2011 Feb;178(2):525-36.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on